BTG's parent company, Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopedics. The company has gained international recognition and expanded rapidly during the last two decades.
Ferring's research activities and products are focused on the provision of tailored treatments that work on the body's own terms to enable doctors to combat numerous diseases and medical conditions. The company has gained international recognition over the last 20 years for the creation of innovative medications that improve the quality of life of children and adults all around the world.
Ferring's marketing, medical services and sales teams led by its corporate headquarters in Saint-Prex, Switzerland, operate from more than 50 countries and employ more than 4500 people throughout the world, while treatments are available in more than 90 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring's R&D projects complement the company's product portfolio and will add a new generation of products to some of the company's most successful specialty brands. R&D facilities are located in Denmark, USA, Israel, India and China.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilizing existing and acquired skills and the development of pioneering technologies, investing in research and development and where necessary, through partnerships with academic institutes and other pharmaceutical and biotech companies.
Ferring and BTG actively search for in-licensing opportunities and product acquisitions in Ferring's key areas of therapeutic activity, Reproductive Health, Endocrinology, Urology, Gastroenterology and Orthopedics.